NAPLEX Quiz: Adverse Drug Event Reporting

What this quiz covers

This quiz focuses on Adverse Drug Event Reporting, giving you a quick way to practice the rules, question types, and explanations that matter most for NAPLEX.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

Question 1

1. Monthly pregnancy testing and periodic lipid panel and liver function tests during therapy (correct answer)
2. Weekly INR monitoring because isotretinoin commonly increases warfarin effect
3. Daily serum potassium monitoring because isotretinoin causes hyperkalemia
4. Routine serum digoxin concentrations because isotretinoin increases digoxin levels

Explanation: This question tests knowledge of isotretinoin monitoring requirements under the iPLEDGE risk management program. Isotretinoin is a known teratogen requiring strict pregnancy prevention and can cause hyperlipidemia and hepatotoxicity, necessitating specific monitoring. Option A is correct because monthly pregnancy testing is mandatory for females of childbearing potential throughout therapy, and periodic lipid panels and liver function tests are required due to elevated baseline triglycerides and potential hepatotoxicity. Option B is incorrect as isotretinoin doesn't significantly affect warfarin. Option C is wrong because isotretinoin doesn't cause hyperkalemia requiring potassium monitoring. Option D is incorrect as isotretinoin doesn't affect digoxin levels. The clinical pearl is that isotretinoin requires enrollment in iPLEDGE with monthly pregnancy tests, two forms of contraception, and monitoring for hyperlipidemia and hepatotoxicity; pharmacists must verify iPLEDGE requirements before dispensing and counsel on teratogenicity risks.

Question 2

1. Instruct the patient to call 911 immediately for possible anaphylaxis, then document the reaction and notify the prescriber; submit a MedWatch report once the patient is stabilized (correct answer)
2. Submit a MedWatch report first to ensure the event is captured, then advise the patient to try diphenhydramine 25 mg by mouth and monitor at home
3. Report the reaction to the Vaccine Adverse Event Reporting System (VAERS) because antibiotics are biologic products
4. Record only that the patient had "rash" without timing or symptoms because detailed information is not needed for adverse event reporting

Explanation: This question tests recognition and management of anaphylaxis as a severe adverse drug reaction. The patient exhibits classic signs of anaphylaxis (generalized hives, lip swelling, throat tightness) within 30 minutes of first amoxicillin/clavulanate dose, indicating IgE-mediated hypersensitivity. Option A is correct because anaphylaxis is a medical emergency requiring immediate 911 activation, followed by proper documentation and MedWatch reporting once the patient is stabilized. Option B is dangerous as it delays emergency treatment to complete paperwork first. Option C is incorrect because VAERS is specifically for vaccine adverse events, not antibiotics. Option D fails to capture critical details needed for adverse event reporting and patient safety. The clinical pearl is that anaphylaxis requires immediate emergency response first, then comprehensive documentation including timing, symptoms, and interventions, followed by FDA MedWatch reporting for serious adverse events. Pharmacists should document beta-lactam allergies prominently in all systems to prevent future exposures.

Question 3

1. Submit a report to FDA MedWatch including product name/manufacturer, lot number if available, dose, timing, and clinical outcome, and advise urgent medical evaluation for symptomatic bradycardia (correct answer)
2. Report the event only to the pharmacy's wholesaler because FDA reports are reserved for prescribers
3. Document the event in the patient profile but do not report externally because hypotension is a known effect of beta-blockers
4. Report the event to VAERS because extended-release products are regulated like vaccines

Explanation: This question tests FDA MedWatch reporting requirements for newly marketed drug products causing serious adverse events. The patient experienced symptomatic bradycardia and hypotension after switching to a new extended-release metoprolol formulation, suggesting possible formulation issues or bioequivalence problems. Option A is correct because FDA MedWatch reports should include specific product identification (name, manufacturer, lot number), dosing details, timing, and clinical outcomes, while the patient needs urgent evaluation for symptomatic bradycardia. Option B is incorrect as pharmacists can and should report directly to FDA. Option C fails to report a potentially serious formulation issue affecting other patients. Option D is incorrect because VAERS is only for vaccines, not extended-release formulations. The clinical pearl is that pharmacists should report serious adverse events with newly marketed products to FDA MedWatch, including specific product details for investigation; bioequivalence issues with modified-release formulations can cause serious clinical consequences requiring vigilant monitoring.

Question 4

1. Implement a weekly-dose methotrexate safety process (explicit "once weekly" directions, day-of-week specified, pharmacist counseling with teach-back, and independent double-check of labels for high-alert medications) (correct answer)
2. Advise the patient to take methotrexate 15 mg by mouth daily with food to reduce gastrointestinal adverse effects
3. Switch the patient to methotrexate 2.5 mg tablets and instruct her to self-adjust the dose based on symptoms
4. Avoid documenting the error in the pharmacy system to reduce liability and prevent patient concern

Explanation: This question tests medication error prevention strategies for high-alert medications. The patient experienced methotrexate toxicity (cytopenias, transaminitis, mucositis) due to a dispensing error resulting in daily instead of weekly administration, a well-documented fatal error pattern. Option A is correct because implementing systematic safety processes including explicit weekly dosing language, day-of-week specification, mandatory counseling with teach-back, and independent double-checks specifically addresses the root cause and prevents recurrence. Option B perpetuates the dangerous daily dosing. Option C inappropriately suggests patient self-adjustment of a high-alert medication. Option D violates patient safety principles by avoiding documentation needed for system improvement. The clinical pearl is that weekly methotrexate requires multiple safety barriers including computer alerts, explicit "once weekly" directions with specific day, mandatory pharmacist counseling, and independent verification; medication errors should always be documented and analyzed to improve systems and prevent future harm.

Question 5

1. Advise holding warfarin and contacting the prescriber urgently to manage supratherapeutic INR and switch antibiotics; counsel on bleeding precautions (correct answer)
2. Recommend increasing warfarin to 7.5 mg by mouth daily because antibiotics reduce warfarin effectiveness
3. Report the event to VAERS because elevated INR suggests an immune-mediated reaction
4. Continue warfarin at the same dose and recheck INR in 4 weeks because gum bleeding is not clinically significant

Explanation: This question tests management of warfarin drug interactions causing supratherapeutic anticoagulation. The patient has a significantly elevated INR (6.2) with bleeding symptoms after starting trimethoprim/sulfamethoxazole, which inhibits CYP2C9 and reduces gut vitamin K production, potentiating warfarin's effect. Option A is correct because warfarin must be held immediately, the prescriber contacted urgently for INR management and antibiotic change, and bleeding precautions counseling provided. Option B is dangerous as it would worsen the already elevated INR. Option C is incorrect because this is a pharmacokinetic interaction, not an immune reaction requiring VAERS reporting. Option D dangerously ignores a critical INR elevation with active bleeding. The clinical pearl is that trimethoprim/sulfamethoxazole significantly increases warfarin effect through dual mechanisms; when antibiotics are needed in warfarin patients, INR should be checked within 3-5 days and alternative antibiotics considered for high-risk patients.

Question 6

1. Recommend continuing both drugs and adding over-the-counter ibuprofen 600 mg by mouth every 6 hours as needed for pain
2. Advise the patient to stop simvastatin immediately, seek urgent evaluation for possible rhabdomyolysis, and contact the prescriber to change the antibiotic (correct answer)
3. Report the event to the Centers for Disease Control and Prevention (CDC) as a vaccine-related adverse event
4. Reassure the patient that muscle pain is expected with clarithromycin and recommend finishing the full antibiotic course without changes

Explanation: This question tests recognition and management of drug-drug interaction-induced rhabdomyolysis. The patient presents with classic signs of rhabdomyolysis (severe muscle pain, dark urine, elevated creatinine, elevated transaminases) occurring after starting clarithromycin while on chronic simvastatin therapy. Clarithromycin is a strong CYP3A4 inhibitor that significantly increases simvastatin levels, leading to myotoxicity. Option B is correct because immediate discontinuation of simvastatin and urgent medical evaluation are critical to prevent progression to acute kidney injury, while the prescriber must be contacted to change the antibiotic. Option A is dangerous as NSAIDs can worsen renal function in rhabdomyolysis. Option C is incorrect because this is a drug interaction, not a vaccine-related event. Option D is dangerous as it dismisses serious symptoms requiring immediate intervention. The clinical pearl is that strong CYP3A4 inhibitors (clarithromycin, erythromycin, itraconazole) are contraindicated with simvastatin and lovastatin; alternative statins (pravastatin, rosuvastatin) or antibiotics (azithromycin) should be used when concurrent therapy is needed.

Question 7

1. Recommend continuing allopurinol and adding over-the-counter hydrocortisone cream because rash is expected when uric acid decreases
2. Advise immediate discontinuation of allopurinol and urgent medical evaluation for possible severe cutaneous adverse reaction; document and report to FDA MedWatch (correct answer)
3. Suggest increasing allopurinol to 600 mg by mouth daily to overcome the reaction and prevent flares
4. Report the event to the CDC because fever and rash suggest a reportable infectious disease

Explanation: This question tests recognition of severe cutaneous adverse reactions (SCARs) requiring immediate intervention. The patient presents with fever, facial swelling, widespread rash, and mouth sores two weeks after starting allopurinol, classic for DRESS syndrome or Stevens-Johnson syndrome, both life-threatening SCARs more common with allopurinol in CKD patients. Option B is correct because immediate discontinuation and urgent medical evaluation are critical for suspected SCARs, with FDA MedWatch reporting required for these serious reactions. Option A dangerously continues the causative agent and trivializes serious symptoms. Option C would worsen the reaction by increasing the dose. Option D incorrectly reports to CDC when this is a drug reaction, not infectious disease. The clinical pearl is that allopurinol-associated SCARs typically occur 2-8 weeks after initiation, with higher risk in renal impairment and certain ethnic groups (HLA-B*5801); fever with rash and mucosal involvement requires immediate drug discontinuation and hospitalization.

Question 8

1. Advise stopping lamotrigine and seeking prompt medical evaluation due to concern for serious rash; notify the prescriber and document the reaction (correct answer)
2. Recommend applying topical antifungal cream and continuing lamotrigine titration as planned
3. Switch lamotrigine to carbamazepine without contacting the prescriber because both treat bipolar disorder
4. Report the event to the manufacturer only and do not document it in the pharmacy profile

Explanation: This question tests the management of lamotrigine-associated rash, potentially indicating serious cutaneous reactions. The key patient-specific factor is the new trunk rash with fever 2 weeks after starting lamotrigine titration in a bipolar patient. Advising to stop lamotrigine and seek prompt evaluation due to serious rash concern while notifying the prescriber and documenting is the best choice because lamotrigine can cause Stevens-Johnson syndrome, especially with rapid titration, requiring immediate cessation. Applying topical antifungal is incorrect as it assumes infection without evidence, while switching to carbamazepine without input risks similar rash potential. Reporting only to the manufacturer omits patient safety and profile documentation. A clinical pearl is to titrate lamotrigine slowly (e.g., 25 mg/week) to minimize rash risk. For reporting, submit to MedWatch for serious rashes, including titration details and resolution post-dechallenge.

Question 9

1. Recommend stopping metformin immediately and continuing empagliflozin because these symptoms are not medication-related
2. Assess for urinary tract infection or genital mycotic infection, refer for prompt evaluation and treatment, counsel on hygiene and hydration, and notify the prescriber if recurrent or severe (correct answer)
3. Report the event to the DEA because empagliflozin is a high-abuse medication
4. Advise the patient to double the empagliflozin dose to 20 mg by mouth daily to resolve urinary symptoms faster

Explanation: This question tests recognition and management of SGLT2 inhibitor-associated genitourinary infections. The patient presents with classic symptoms of urinary tract infection or genital mycotic infection (dysuria, frequency, genital itching) after starting empagliflozin, which increases urinary glucose creating a favorable environment for infections. Option B is correct because assessment for UTI versus mycotic infection is needed, prompt evaluation and treatment are required, hygiene and hydration counseling help prevent recurrence, and the prescriber should be notified if infections are recurrent or severe. Option A incorrectly stops metformin instead of addressing the actual cause. Option C is incorrect as empagliflozin is not DEA-controlled. Option D dangerously suggests doubling the dose, which would worsen infection risk. The clinical pearl is that SGLT2 inhibitors significantly increase risk of genitourinary infections through glucosuria; patients should be counseled on hygiene measures, hydration, and early symptom recognition, with consideration for discontinuation if infections are recurrent.

Question 10

1. Advise removing the fentanyl patch and calling emergency services immediately; recommend naloxone administration if available and notify the prescriber about opioid/benzodiazepine risk (correct answer)
2. Advise applying a heating pad over the patch to improve analgesia and reduce sedation
3. Recommend taking an extra dose of clonazepam to counteract agitation from opioids
4. Report the event only to MedWatch and do not recommend urgent care because sedation is expected early in therapy

Explanation: This question tests the response to opioid overdose symptoms exacerbated by concurrent benzodiazepine use. The key patient-specific factor is the excessive sleepiness and difficulty arousing two days after starting fentanyl patch, with low respiratory rate and clonazepam use. Advising to remove the patch, call emergency services, administer naloxone if available, and notify the prescriber about interaction risks is the best choice because it addresses respiratory depression promptly, and the combination increases CNS depression. Applying a heating pad is incorrect as it enhances fentanyl absorption, worsening overdose, while extra clonazepam exacerbates sedation. Reporting only to MedWatch delays acute care. A clinical pearl is to avoid opioid-benzodiazepine combinations per FDA warnings, using alternatives for anxiety. For reporting, document overdoses in MedWatch with details on polypharmacy and reversal agents used.

Question 11

1. Recommend doubling the potassium chloride dose and continuing digoxin 0.25 mg by mouth daily without contacting the prescriber
2. Advise the patient to stop digoxin and seek prompt medical evaluation; contact the prescriber about the dosing error and document the medication error per pharmacy policy (correct answer)
3. Report the event to the Drug Enforcement Administration (DEA) because digoxin is a controlled substance
4. Reassure the patient that visual changes are a normal adjustment effect and recommend continuing the current regimen for 2 more weeks

Explanation: This question tests recognition of digoxin toxicity and medication error management. The patient presents with classic digoxin toxicity symptoms (nausea, anorexia, yellow vision) after an apparent dosing error during hospital discharge, confirmed by elevated digoxin level (2.6 ng/mL) and predisposing factors (elderly, CKD, hypokalemia). Option B is correct because immediate discontinuation and medical evaluation are essential, the prescriber must be contacted about the dosing error, and the medication error requires documentation per pharmacy policy for quality improvement. Option A is dangerous as it continues toxic digoxin dosing and worsens hypokalemia. Option C is incorrect because digoxin is not a controlled substance requiring DEA reporting. Option D dangerously dismisses serious toxicity symptoms. The clinical pearl is that digoxin has a narrow therapeutic index with increased toxicity risk in elderly patients, renal impairment, and hypokalemia; medication reconciliation at transitions of care is critical to prevent dosing errors, and all medication errors should be documented for system improvement.

Question 12

1. Recommend continuing lisinopril and starting dextromethorphan as needed because ACE inhibitor cough is self-limited
2. Recommend the patient stop lisinopril and contact the prescriber to switch to an angiotensin II receptor blocker (ARB) (correct answer)
3. Report the cough to the Vaccine Adverse Event Reporting System (VAERS) as a serious adverse event
4. Increase lisinopril to 20 mg daily to overcome tolerance and reduce the cough

Explanation: This question tests the recognition and management of angiotensin-converting enzyme (ACE) inhibitor-induced cough as an adverse drug event. The key patient-specific factor is the new-onset dry cough starting 10 days after initiating lisinopril, with no signs of infection or other respiratory issues. Recommending discontinuation of lisinopril and switching to an angiotensin II receptor blocker (ARB) is the best choice because ACE inhibitor cough is mediated by bradykinin accumulation, which ARBs do not cause, providing effective hypertension control without this side effect. Continuing lisinopril with dextromethorphan is incorrect as the cough is not self-limited and may persist or worsen, while reporting to VAERS is inappropriate since it is for vaccine-related events, not medications. Increasing the lisinopril dose is suboptimal as it will not resolve the cough and may increase the risk of other adverse effects like hyperkalemia. A key clinical pearl is to always assess the temporal relationship between medication initiation and symptom onset when evaluating potential adverse drug events. For reporting, pharmacists should document such events in the patient profile and notify the prescriber to facilitate appropriate management and prevent recurrence.

Question 13

1. Recommend increasing digoxin to 0.5 mg daily to improve rate control
2. Advise prompt medical evaluation for suspected digoxin toxicity, recommend checking a digoxin level and electrolytes, and address hypokalemia risk (correct answer)
3. Recommend taking digoxin with food and continuing the same dose because visual changes are benign
4. Report the event to VAERS because visual changes are a reportable vaccine adverse event

Explanation: This question tests the recognition and management of digoxin toxicity in a patient with renal impairment and hypokalemia. The key patient-specific factor is the nausea, anorexia, and visual halos two weeks after starting digoxin, with low potassium and elevated SCr. Advising prompt evaluation for digoxin toxicity, checking levels and electrolytes, and addressing hypokalemia is the best choice because toxicity is exacerbated by hypokalemia and renal dysfunction, requiring dose adjustment or discontinuation. Increasing digoxin is incorrect as it would worsen toxicity, while taking with food does not mitigate serious symptoms. Reporting to VAERS is inappropriate for non-vaccine events. A transferable pearl is to recognize classic digoxin toxicity symptoms (GI, visual, cardiac) and maintain potassium >4 mEq/L. In adverse event management, use therapeutic drug monitoring and report severe cases to MedWatch with levels and contributing factors.

Question 14

1. Recommend increasing isotretinoin dose to improve acne control and reassess mood at the next refill
2. Advise immediate contact with the prescriber for urgent evaluation of mood changes and ensure appropriate safety assessment; counsel on supportive care for cheilitis and document/report as appropriate (correct answer)
3. Report the event to VAERS because isotretinoin is a regulated medication with a risk management program
4. Recommend stopping oral contraception to reduce triglycerides while continuing isotretinoin

Explanation: This question tests the management of psychiatric and dermatologic adverse effects associated with isotretinoin therapy. The key patient-specific factor is the new onset of depressed mood with passive suicidal thoughts and severe dry lips (cheilitis) after 6 weeks of isotretinoin use, alongside elevated triglycerides. Advising immediate prescriber contact for mood evaluation and safety assessment while counseling on cheilitis supportive care and documenting the event is the best choice because isotretinoin is linked to mood changes requiring urgent intervention, and the iPLEDGE program mandates monitoring. Increasing the isotretinoin dose is incorrect as it may worsen adverse effects without addressing mood, while reporting to VAERS is inappropriate for non-vaccine drugs. Recommending to stop oral contraception is suboptimal as it risks pregnancy, a contraindication for isotretinoin, and does not address triglycerides directly. A clinical pearl is to screen for depression at each isotretinoin visit using tools like PHQ-2. For reporting, use MedWatch for serious events like suicidality, ensuring details on timing and labs are included.

Question 15

1. Recommend adding aspirin 81 mg daily for additional clot prevention while continuing naproxen
2. Assess bleeding severity and advise prompt medical evaluation; recommend avoiding NSAIDs like naproxen while on apixaban and contact the prescriber regarding bleeding risk (correct answer)
3. Recommend increasing apixaban to 10 mg twice daily long-term to reduce clot burden and prevent bruising
4. Report the event to VAERS because anticoagulants are monitored through vaccine safety systems

Explanation: This question tests the management of bleeding adverse events in patients on direct oral anticoagulants (DOACs) with interacting medications. The key patient-specific factor is the new bruising and nosebleeds with low hemoglobin 2 weeks after starting apixaban, concurrent with naproxen initiation. Assessing bleeding severity, advising prompt evaluation, recommending NSAID avoidance, and contacting the prescriber is the best choice because NSAIDs increase DOAC bleeding risk via platelet inhibition, requiring intervention. Adding aspirin worsens bleeding, while increasing apixaban is incorrect as it heightens risk without benefit. Reporting to VAERS is inappropriate for anticoagulants. A transferable pearl is to counsel on avoiding OTC NSAIDs with DOACs and monitor for bleeding signs like bruising. In adverse event management, use a framework assessing bleed site, severity, and reversibility, reporting major bleeds to MedWatch.

Question 16

1. Advise the patient to skip the next dose and resume the same regimen tomorrow if symptoms improve
2. Call emergency services immediately for suspected opioid overdose, initiate naloxone if available per protocol, and notify the prescriber and pharmacy management per medication error policy (correct answer)
3. Report the event only to MedWatch and wait for FDA guidance before taking further action
4. Recommend taking diphenhydramine 50 mg to counteract opioid effects and improve alertness

Explanation: This question tests the response to a medication dispensing error involving opioid overdose symptoms as an adverse event. The key patient-specific factor is the erroneous dispensing of oxycodone 30 mg instead of 5 mg, leading to excessive sedation, pinpoint pupils, and low respiratory rate after two days of use. Calling emergency services for suspected opioid overdose, initiating naloxone if available, and notifying the prescriber and pharmacy management per error policy is the best choice because it addresses life-threatening respiratory depression promptly and ensures error documentation for quality improvement. Advising to skip the next dose is incorrect as it does not address current overdose symptoms, while reporting only to MedWatch delays urgent care. Recommending diphenhydramine is suboptimal as it could worsen sedation without reversing opioid effects. A transferable pearl is to recognize opioid toxicity triad (sedation, miosis, respiratory depression) and prioritize reversal with naloxone. In adverse event reporting, follow ISMP guidelines for medication errors, including root cause analysis and voluntary submission to FDA or state boards.

Question 17

1. Recommend continuing allopurinol and adding topical hydrocortisone for the rash
2. Advise immediate emergency evaluation for suspected severe cutaneous adverse reaction and instruct the patient to stop allopurinol; ensure the reaction is documented and reported (correct answer)
3. Switch the patient to febuxostat without contacting the prescriber because it is in the same class
4. Report the event to VAERS because it involves fever and rash

Explanation: This question tests the recognition and management of allopurinol hypersensitivity syndrome (AHS) as a severe adverse drug event. The key patient-specific factor is the onset of fever, facial swelling, widespread painful rash, dark urine, and elevated liver enzymes 12 days after starting allopurinol, with rising SCr. Advising immediate emergency evaluation for suspected severe cutaneous adverse reaction and stopping allopurinol while documenting and reporting is the best choice because AHS can progress to life-threatening organ involvement, requiring prompt discontinuation. Continuing allopurinol with topical hydrocortisone is incorrect as it does not address systemic involvement, while switching to febuxostat without prescriber input risks similar reactions in susceptible patients. Reporting to VAERS is inappropriate for non-vaccine events. A clinical pearl is to screen for HLA-B*5801 in high-risk populations before allopurinol initiation to prevent AHS. For reporting, use MedWatch for serious reactions, including details on genetics, labs, and dechallenge outcomes.

Question 18

1. Advise stopping nitrofurantoin and seeking prompt medical evaluation for possible pulmonary reaction; document and notify the prescriber (correct answer)
2. Recommend continuing nitrofurantoin because respiratory symptoms are expected with urinary antibiotics
3. Recommend adding codeine cough syrup and completing the antibiotic course without contacting the prescriber
4. Report the event to VAERS because nitrofurantoin reactions are vaccine-related

Explanation: This question tests the recognition and management of nitrofurantoin-induced pulmonary toxicity as an adverse drug event. The key patient-specific factor is the onset of shortness of breath, fever, and cough on day 3 of nitrofurantoin therapy, with low oxygen saturation. Advising to stop nitrofurantoin and seek prompt medical evaluation for possible pulmonary reaction while documenting and notifying the prescriber is the best choice because nitrofurantoin can cause acute pneumonitis, and early discontinuation improves outcomes. Continuing nitrofurantoin is incorrect as respiratory symptoms are not expected and may worsen, while adding codeine ignores the underlying cause. Reporting to VAERS is inappropriate for non-vaccine drugs. A clinical pearl is to monitor for pulmonary symptoms in nitrofurantoin users, especially with prolonged therapy. For reporting, use MedWatch for rare events like this, including dechallenge response and imaging if available.

Question 19

1. Counsel to avoid alcohol during metronidazole therapy and for at least 3 days after the last dose, and provide supportive care guidance (correct answer)
2. Recommend switching to disulfiram to treat the reaction and allow continued alcohol use
3. Advise taking metronidazole with alcohol to reduce gastrointestinal upset
4. Report the event to VAERS because it resembles a vaccine-related reaction

Explanation: This question tests the prevention of disulfiram-like reactions from metronidazole-alcohol interactions. The key patient-specific factor is the flushing, nausea, vomiting, and palpitations after consuming alcohol on day 4 of metronidazole therapy. Counseling to avoid alcohol during and for 3 days after metronidazole, with supportive care guidance, is the best recommendation because metronidazole inhibits aldehyde dehydrogenase, causing accumulation of acetaldehyde and symptoms. Switching to disulfiram is incorrect as it is for alcohol deterrence, not reaction treatment, while taking with alcohol worsens effects. Reporting to VAERS is inappropriate for this interaction. A clinical pearl is to extend alcohol avoidance to 72 hours post-metronidazole due to its half-life. For prevention, include interaction warnings in counseling and document patient education in adverse event frameworks.

Question 20

1. Dispense as written because the prescriber likely intended daily dosing for faster symptom relief
2. Clarify and correct directions to once-weekly dosing before dispensing, provide explicit counseling on weekly administration, and document the near-miss per pharmacy policy (correct answer)
3. Advise the patient to take it daily for 7 days then stop, without contacting the prescriber
4. Report the labeling error only to VAERS because methotrexate is a high-alert medication

Explanation: This question tests the prevention of adverse events from methotrexate dosing errors in rheumatoid arthritis treatment. The key patient-specific factor is the labeling error directing daily instead of weekly methotrexate 15 mg, a high-alert medication. Clarifying and correcting to once-weekly dosing before dispensing, providing counseling, and documenting the near-miss is the best choice because weekly dosing prevents toxicity like pancytopenia, and error reporting improves safety. Dispensing as written risks severe harm from overdose, while advising daily for 7 days ignores standard regimens. Reporting only to VAERS is suboptimal for non-vaccine errors. A clinical pearl is to verify methotrexate directions and counsel on folic acid supplementation to mitigate risks. For adverse event prevention, use tall man lettering and double-checks for high-alert drugs, reporting near-misses to ISMP.